$XBI $154.29 -3% 📉
Want to access our searchable database of catalysts and more? Get access to BiopharmIQ for 30 days free, no credit card required. Check it out here!
Covid Updates
$NVAX -12% Enrollment complete in pivotal ph 3 trial in US and Mexico. source
Pipeline Updates
$CYDY -19% Unblinded ph 2/3 data for the CD12 Covid-19 trial but is talking with regulatory agencies before releasing the data and meeting details. source
$OTIC -44% Ph 3 trial of OTIVIDEX for Ménière's disease failed. Company will turn focus to other assets in pipeline. source
$SUPN -1% Received notice from the U.S. Food and Drug Administration (FDA) that the company’s New Drug Application (NDA) resubmission for SPN-812 for the treatment of ADHD in pediatric patients is considered a Class I resubmission thereby assigning a timeline of two months for review by the FDA and establishing a new Prescription Drug User Fee Act (PDUFA) target action date in early April 2021. source
$SAVA -5% Alignment with FDA on two registrational phase 3 trials to be initiated in H2 2021. source
$RVNC -4% Mixed-positive phase 2 data released. company plans to conduct an end-of-phase-2 meeting with FDA prior to initiating phase 3 program. source
Financial Updates
$ARCT -11% acquires exclusive license to mRNA manufacturing technology from Alexion Pharma. source